Inhibition of rat liver fibrogenesis through noradrenergic antagonism
Related Experiment Video
Updated: Oct 2, 2026
The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat
Published on: June 17, 2016
Liliane Dubuisson1, Alexis Desmoulière, Boris Decourt
1Groupe de Recherches pour l'Etude du Foie, INSERM E9917, Université Victor Segalen Bordeaux 2, Bordeaux, France.
Abstract:
The effect of adrenergic innervation and/or circulating catecholamines on the function of liver fibrogenic cells is poorly understood. Our aim was to investigate the effects of noradrenergic antagonism on carbon tetrachloride (CCl4)-induced liver fibrosis in rats. Two weeks of CCl4 induced an approximately 5-fold increase in the area of fibrosis as compared with controls. The addition of 6-hydroxydopamine (OHDA), a toxin that destroys noradrenergic fibers, decreased fibrosis by 60%. After 6 weeks of CCl4, the area of fibrosis increased about 30-fold in CCl4-treated animals and was decreased by 36% with OHDA. At 2 weeks, OHDA abrogated the CCl4-induced increase in mRNA level of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), an inhibitor of extracellular matrix degradation, and it greatly reduced it at 6 weeks. Finally, when rats treated with CCl4 for 2 weeks also received prazosin, an antagonist of alpha1-adrenergic receptors, fibrosis was decreased by 83%. In conclusion, destruction of noradrenergic fibers or antagonism of noradrenergic signaling through alpha1 receptors inhibited the development of liver fibrosis. Because adrenoreceptor antagonists have a very sound safety profile, they appear as attractive drugs to reduce liver fibrogenesis.
Insights
Noradrenergic signaling promotes liver fibrosis. Blocking these pathways with 6-hydroxydopamine (OHDA) or prazosin significantly reduced fibrosis in a rat model, suggesting potential therapeutic strategies.
Area of Science:
- Hepatology
- Fibrosis research
- Adrenergic signaling
Background:
- The role of adrenergic innervation and catecholamines in liver fibrogenesis is not well understood.
- Liver fibrosis, a precursor to cirrhosis, involves excessive extracellular matrix deposition.
- Understanding regulatory pathways is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the impact of noradrenergic antagonism on carbon tetrachloride (CCl4)-induced liver fibrosis in rats.
- To evaluate the efficacy of 6-hydroxydopamine (OHDA) and prazosin in mitigating liver fibrosis.
- To explore the modulation of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) by noradrenergic signaling.
Main Methods:
- Induction of liver fibrosis in rats using carbon tetrachloride (CCl4).
- Administration of 6-hydroxydopamine (OHDA) to destroy noradrenergic fibers.
- Treatment with prazosin, an alpha1-adrenergic receptor antagonist.
- Assessment of fibrosis area and mRNA levels of TIMP-1.
Main Results:
- CCl4 administration led to a significant increase in liver fibrosis area.
- OHDA treatment reduced fibrosis by 60% at 2 weeks and 36% at 6 weeks.
- Prazosin decreased fibrosis by 83% after 2 weeks of CCl4 treatment.
- OHDA abrogated or greatly reduced CCl4-induced increases in TIMP-1 mRNA levels.
Conclusions:
- Noradrenergic fibers and alpha1-adrenergic receptor signaling play a significant role in promoting liver fibrosis.
- Inhibiting noradrenergic pathways effectively reduces liver fibrogenesis in a rat model.
- Adrenoreceptor antagonists represent promising therapeutic agents for managing liver fibrosis due to their safety profile.
